LOW
58
2
BLK
75
3
ROP
62
-3
SO
55
-2
MRK
27
-3
CI
68
13
ACN
49
2
CRM
75
8
NI
73
3
AMT
34
-2
STT
67
3
WHR
72
2
MSI
79
-2
NTAP
62
-2
GT
64
-3
LNC
50
5
KMX
61
3
PBI
68
3
DOV
71
2
SRE
69
3
LOW
58
2
BLK
75
3
ROP
62
-3
SO
55
-2
MRK
27
-3
CI
68
13
ACN
49
2
CRM
75
8
NI
73
3
AMT
34
-2
STT
67
3
WHR
72
2
MSI
79
-2
NTAP
62
-2
GT
64
-3
LNC
50
5
KMX
61
3
PBI
68
3
DOV
71
2
SRE
69
3
Financhill
Back

Zevra Therapeutics Quote, Financials, Valuation and Earnings

Write This Down: Tuesday at 2 p.m. ET!

Don't Miss Our LIVE Trade
Buy
67

ZVRA
Zevra Therapeutics

Last Price:
8.55
Seasonality Move:
4.71%

7 Day Trial

ALL ACCESS PASS

$ 7

U.S. Government Report Alert Tuesday

Discover the Secret Loophole

Zevra Therapeutics Price Quote

$8.55
-0.40 (-4.47%)
(Updated: November 12, 2024 at 5:55 PM ET)

Zevra Therapeutics Key Stats

Buy
67
Zevra Therapeutics (ZVRA) is a Buy
Day range:
$8.76 - $9.04
52-week range:
$3.89 - $9.04
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
14.92
P/B ratio:
14.5%
Volume:
579K
Avg. volume:
692.3K
1-year change:
115.66%
Market cap:
$470.9M
Revenue:
$27.5M
EPS:
$-1.68

How Much Does Zevra Therapeutics Make?

Is Zevra Therapeutics Growing As A Company?

  • What Is Zevra Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -0.47%
  • What Is Zevra Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Zevra Therapeutics Stock Price Performance

What Is Zevra Therapeutics 52-Week High & Low?

Zevra Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Zevra Therapeutics?

  • How Much Debt Does Zevra Therapeutics Have?
    Total long term debt quarterly is $58.3M
  • How Much Cash Does Zevra Therapeutics Have?
    Cash and short term investments quarterly total is $49.3M
  • What Is Zevra Therapeutics’s Book Value Per Share?
    Book value per share is 0.77

Is Zevra Therapeutics Cash Flow Positive?

  • What Is ZVRA Cash Flow From Operations?
    Cash flow from operations (TTM) is -$56.1M
  • What Is Zevra Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $47.8M
  • What Is Zevra Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$19.2M

Zevra Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    ZVRA return on invested capital is -68.51%
  • What Is Zevra Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -46.14%
  • What Is ZVRA Return On Equity?
    ROE is a measure of profitability and is -117.77%

Zevra Therapeutics Earnings Date & Stock Price

Zevra Therapeutics Competitors

  • Who Are Zevra Therapeutics's Competitors?
    Below is a list of companies who compete with Zevra Therapeutics or are related in some way:
    • BioCardia Inc (BCDA)
    • Ionis Pharmaceuticals Inc (IONS)
    • Instil Bio Inc (TIL)
    • Vanda Pharmaceuticals Inc (VNDA)
    • Xeris Biopharma Holdings Inc (XERS)

Zevra Therapeutics Dividend Yield

Zevra Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -9.92%
Revenue: -47.47% 2.09%

Analyst Recommendations

Buy Recommendations: 4
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 20.43
Upside from Last Price: 128.25%

Major Shareholders

  • How many ZVRA shares are owned by institutional investors?
    30.8M ZVRA shares are owned by institutional investors
  • How many ZVRA shares are owned by insiders?
    286.6K ZVRA shares are owned by insiders